News Snapshot:
Brazil’s Butantan Institute released numbers calling into question the efficacy of China’s CoronaVac vaccine Wednesday, prompting China to respond in order to clarify the numbers. Butantan is in final-stage trials for CoronaVac, a COVID-19 vaccine manufactured by China’s SinoVac, and submitted results to Brazilian regulators Tuesday declaring an efficacy rate of just over 50%, according to the South China Morning Post . A week prior, Butantan, a partner of SinoVac, submitted results indicating CoronaVac was 78% effective in preventing mild cases of COVID-19 and 100% effective in preventing severe cases, according to SCMP. How effective is China’s Sinovac vaccine? Experts...
